- Home
- FLNG vs SNDX Comparison
FLNG vs SNDX Comparison
Compare FLNG & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLNG
- SNDX
- Stock Information
- Founded
- FLNG 2006
- SNDX 2005
- Country
- FLNG Bermuda
- SNDX United States
- Employees
- FLNG N/A
- SNDX N/A
- Industry
- FLNG Marine Transportation
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- FLNG Consumer Discretionary
- SNDX Health Care
- Exchange
- FLNG Nasdaq
- SNDX Nasdaq
- Market Cap
- FLNG 1.3B
- SNDX 1.3B
- IPO Year
- FLNG N/A
- SNDX 2016
- Fundamental
- Price
- FLNG $24.97
- SNDX $16.38
- Analyst Decision
- FLNG Hold
- SNDX Strong Buy
- Analyst Count
- FLNG 1
- SNDX 10
- Target Price
- FLNG $23.00
- SNDX $38.40
- AVG Volume (30 Days)
- FLNG 404.5K
- SNDX 1.9M
- Earning Date
- FLNG 11-11-2025
- SNDX 11-04-2025
- Dividend Yield
- FLNG 11.93%
- SNDX N/A
- EPS Growth
- FLNG N/A
- SNDX N/A
- EPS
- FLNG 1.83
- SNDX N/A
- Revenue
- FLNG $355,837,000.00
- SNDX $77,933,000.00
- Revenue This Year
- FLNG N/A
- SNDX $642.36
- Revenue Next Year
- FLNG $3.56
- SNDX $108.58
- P/E Ratio
- FLNG $13.83
- SNDX N/A
- Revenue Growth
- FLNG N/A
- SNDX 2126.66
- 52 Week Low
- FLNG $19.46
- SNDX $8.58
- 52 Week High
- FLNG $27.67
- SNDX $22.50
- Technical
- Relative Strength Index (RSI)
- FLNG 44.64
- SNDX 59.66
- Support Level
- FLNG $24.86
- SNDX $14.93
- Resistance Level
- FLNG $25.40
- SNDX $15.99
- Average True Range (ATR)
- FLNG 0.47
- SNDX 0.66
- MACD
- FLNG -0.04
- SNDX 0.06
- Stochastic Oscillator
- FLNG 26.14
- SNDX 77.97
About FLNG FLEX LNG Ltd.
Flex LNG Ltd is an LNG shipping company with a fleet of next-generation LNG carriers with large cargo capacity. The fleet consists of thirteen modern LNG ships, ten existing and three under construction for delivery. All LNG carriers are equipped with slow-speed, two-stroke engines MEGI or X-DF propulsion which will provide Charterers with tonnage offering advantages in form of reduced fuel consumption and lowered boil-off rates.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.